Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges - Takeaways - MDSpire

Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges

  • By

  • Wenfang Hu

  • Zhongyu Zhang

  • Mengyao Pan

  • Weiye Wang

  • Zibing Wang

  • May 7, 2026

  • 0 min

Share

  • 1

    TCR-T therapy targets intracellular antigens via HLA presentation, enhancing treatment options for solid tumors beyond surface proteins.

  • 2

    Clinical efficacy of TCR-T therapy is inconsistent due to HLA restriction, antigen heterogeneity, and immunosuppressive tumor microenvironments.

  • 3

    Durable tumor control requires not only target recognition but also effective antigen presentation and T-cell fitness.

  • 4

    Emerging strategies to enhance TCR-T therapy include precision receptor engineering and multi-HLA target development.

  • 5

    Broader benefits from TCR-T therapy will necessitate advances in target selection, safety design, and cellular engineering.

Original Source(s)

Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges

  • by Wenfang Hu, Zhongyu Zhang, Mengyao Pan, Weiye Wang, Zibing Wang

  • May 7, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Management of toxicities from antibody – drug conjugates in breast cancer

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen